What is Hyloris Pharmaceuticals Book Value per Share?
Hyloris Pharmaceuticals's book value per share for the quarter that ended in Dec. 2023 was €1.39.
During the past 12 months, Hyloris Pharmaceuticals's average Book Value Per Share Growth Rate was -29.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -15.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Hyloris Pharmaceuticals was -15.40% per year. The lowest was -15.40% per year. And the median was -15.40% per year.
During the past 8 years, the highest P/B Ratio of Hyloris Pharmaceuticals was 10.78. The lowest was 4.16. And the median was 6.71.
Hyloris Pharmaceuticals Book Value per Share Historical Data
The historical data trend for Hyloris Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Hyloris Pharmaceuticals Book Value per Share Chart
Competitive Comparison of Hyloris Pharmaceuticals's Book Value per Share
For the Biotechnology subindustry, Hyloris Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's PB Ratio falls into.
Hyloris Pharmaceuticals Book Value per Share Calculation
Hyloris Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Hyloris Pharmaceuticals (LTS:0AB6) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Hyloris Pharmaceuticals Book Value per Share Related Terms
Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Hyloris Pharmaceuticals (LTS:0AB6) Business Description
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0AB6 has been successfully added to your 